Advertisement

Diabetologia

pp 1–11 | Cite as

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

  • Natasha C. Bergmann
  • Asger Lund
  • Lærke S. Gasbjerg
  • Emma C. E. Meessen
  • Maria M. Andersen
  • Sigrid Bergmann
  • Bolette Hartmann
  • Jens J. Holst
  • Lene Jessen
  • Mikkel B. Christensen
  • Tina Vilsbøll
  • Filip K. KnopEmail author
Article

Abstract

Aims/hypothesis

Glucagon-like peptide 1 (GLP-1) reduces appetite and energy intake in humans, whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), seems to have no effect on eating behaviour. Interestingly, studies in rodents have shown that concomitant activation of GIP and GLP-1 receptors may potentiate the satiety-promoting effect of GLP-1, and a novel dual GLP-1/GIP receptor agonist was recently shown to trigger greater weight losses compared with a GLP-1 receptor agonist in individuals with type 2 diabetes. The aim of this study was to delineate the effects of combined GIP and GLP-1 receptor activation on energy intake, appetite and resting energy expenditure in humans.

Methods

We examined 17 overweight/obese men in a crossover design with 5 study days. On day 1, a 50 g OGTT was performed; on the following 4 study days, the men received an isoglycaemic i.v. glucose infusion (IIGI) plus saline (154 mmol/l NaCl; placebo), GIP (4 pmol kg−1 min−1), GLP-1 (1 pmol kg−1 min−1) or GIP+GLP-1 (4 and 1 pmol kg−1 min−1, respectively). All IIGIs were performed in a randomised order blinded for the participant and the investigators. The primary endpoint was energy intake as measured by an ad libitum meal after 240 min. Secondary endpoints included appetite ratings and resting energy expenditure, as well as insulin, C-peptide and glucagon responses.

Results

Energy intake was significantly reduced during IIGI+GLP-1 compared with IIGI+saline infusion (2715 ± 409 vs 4483 ± 568 kJ [mean ± SEM, n = 17], p = 0.014), whereas there were no significant differences in energy intake during IIGI+GIP (4062 ± 520 kJ) or IIGI+GIP+GLP-1 (3875 ± 451 kJ) infusion compared with IIGI+saline (p = 0.590 and p = 0.364, respectively). Energy intake was higher during IIGI+GIP+GLP-1 compared with IIGI+GLP-1 infusion (p = 0.039).

Conclusions/interpretation

While GLP-1 infusion lowered energy intake in overweight/obese men, simultaneous GIP infusion did not potentiate this GLP-1-mediated effect.

Trial registration

ClinicalTrials.gov NCT02598791

Funding

This study was supported by grants from the Innovation Fund Denmark and the Vissing Foundation.

Keywords

Appetite Dual receptor agonism Energy expenditure Energy intake Glucagon-like peptide 1 Glucose-dependent insulinotropic polypeptide Obesity Overweight 

Abbreviations

GIP

Glucose-dependent insulinotropic polypeptide

GLP-1

Glucagon-like peptide 1

IIGI

Isoglycaemic i.v. glucose infusion

ISR

Insulin secretion rate

REE

Resting energy expenditure

rmANOVA

Repeated measures ANOVA

Notes

Acknowledgements

The authors would like to thank all study participants and acknowledge invaluable laboratory assistance from A. Rasmussen-Lanng, S. M. Schmidt and I. al Nachar, all from Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, Denmark. Part of this work has been presented at the annual meeting of the European Association for the Study of Diabetes, 11–15 September 2017, Lisbon, Portugal, and published as an abstract in Diabetologia 2017;60(Suppl 1):5.

Contribution statement

NCB was involved in planning the study, conducting clinical experiments and statistical analyses, and writing the manuscript. AL was involved in planning the study. LSG was involved in planning the study, conducting clinical experiments, analysing the plasma samples for GIP, GLP-1 and glucagon, and statistical analyses. ECEM, MMA and SB were involved in conducting clinical experiments. BH and JJH analysed plasma samples for GIP, GLP-1 and glucagon. LJ, MC and TV were involved in planning the study. FKK conceptualised the study and was involved in planning the study and writing the manuscript. All authors critically reviewed the manuscript and approved the version to be published. NCB and FKK are the guarantors of the work.

Funding

This study was supported by grants from the Innovation Fund Denmark (grant no. 4135-00091B) and the Vissing Foundation. The funders were not involved in the design of the study, collection, analysis or interpretation of data, preparation of the manuscript; or the decision to publish.

Duality of interest

NCB holds an unrestricted grant from the Innovation Fund Denmark and is employed as a PhD student at Zealand Pharma in collaboration with Steno Diabetes Center Copenhagen, Gentofte Hospital. LSG is a minority shareholder in Antag Therapeutics. LJ is employee of Zealand Pharma. JJH has served on advisory panels for GlaxoSmithKline, Novo Nordisk, Zealand Pharma, AstraZeneca, MSD, Intarcia and Hanmi and as a consultant for Novo Nordisk, and has received research support from Merck, Sharp & Dome. FKK has received lecture fees from, participated in advisory boards of, consulted for and/or received research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD/Merck, Novo Nordisk, Sanofi and Zealand Pharma, and is a minority shareholder in Antag Therapeutics. AL, ECEM, MMA, SB, BH, MC and TV declare no duality of interest associated with their contribution to this manuscript.

Supplementary material

125_2018_4810_MOESM1_ESM.pdf (323 kb)
ESM (PDF 322 kb)

References

  1. 1.
    Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837.  https://doi.org/10.1016/j.cmet.2013.04.008 CrossRefPubMedGoogle Scholar
  2. 2.
    Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101(3):515–520.  https://doi.org/10.1172/JCI990 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Flint A, Raben A, Ersbøll AK et al (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25(6):781–792.  https://doi.org/10.1038/sj.ijo.0801627 CrossRefPubMedGoogle Scholar
  4. 4.
    Shalev A, Holst JJ, Keller U (1997) Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Investig 27:10–16CrossRefGoogle Scholar
  5. 5.
    Horowitz M, Flint A, Jones KL et al (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97(2):258–266.  https://doi.org/10.1016/j.diabres.2012.02.016 CrossRefPubMedGoogle Scholar
  6. 6.
    Asmar M, Tangaa W, Madsbad S et al (2010) On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 298(3):E614–E621.  https://doi.org/10.1152/ajpendo.00639.2009 CrossRefPubMedGoogle Scholar
  7. 7.
    Finan B, Ma T, Ottaway N et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5(209):209ra151.  https://doi.org/10.1126/scitranslmed.3007218 CrossRefPubMedGoogle Scholar
  8. 8.
    Gault VA, Kerr BD, Harriott P, Flatt PR (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci (Lond) 121(3):107–117.  https://doi.org/10.1042/CS20110006 CrossRefGoogle Scholar
  9. 9.
    Nørregaard PK, Deryabina MA, Tofteng Shelton P et al (2017) A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab 20(1):1–9.  https://doi.org/10.1111/dom.13034 CrossRefGoogle Scholar
  10. 10.
    Daousi C, Wilding JPH, Aditya S et al (2009) Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 71(2):195–201.  https://doi.org/10.1111/j.1365-2265.2008.03451.x CrossRefGoogle Scholar
  11. 11.
    Ørskov C, Rabenhøj L, Wettergren A et al (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4):535–539.  https://doi.org/10.2337/diab.43.4.535 CrossRefPubMedGoogle Scholar
  12. 12.
    Lindgren O, Carr RD, Deacon CF et al (2011) Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 96(8):2519–2524.  https://doi.org/10.1210/jc.2011-0266 CrossRefPubMedGoogle Scholar
  13. 13.
    Gregersen NT, Flint A, Bitz C et al (2008) Reproducibility and power of ad libitum energy intake assessed by repeated single meals. Am J Clin Nutr 87(5):1277–1281.  https://doi.org/10.1093/ajcn/87.5.1277 CrossRefPubMedGoogle Scholar
  14. 14.
    Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50(3):253–264.  https://doi.org/10.1016/0169-2607(96)01755-5 CrossRefGoogle Scholar
  15. 15.
    Blundell J, Finlayson G, Axelsen M et al (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19(9):1242–1251.  https://doi.org/10.1111/dom.12932 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Näslund E, Barkeling B, King N et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23(3):304–311.  https://doi.org/10.1038/sj.ijo.0800818 CrossRefPubMedGoogle Scholar
  17. 17.
    Chaput J-P, Tremblay A (2009) The glucostatic theory of appetite control and the risk of obesity and diabetes. Int J Obes 33(1):46–53.  https://doi.org/10.1038/ijo.2008.221
  18. 18.
    Vilsbøll T, Agersø H, Lauritsen T et al (2006) The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137(3):168–172.  https://doi.org/10.1016/j.regpep.2006.07.007 CrossRefPubMedGoogle Scholar
  19. 19.
    Vilsbøll T, Agersø H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88(1):220–224.  https://doi.org/10.1210/jc.2002-021053 CrossRefPubMedGoogle Scholar
  20. 20.
    Verdich C, Flint A, Gutzwiller J-P et al (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382–4389PubMedGoogle Scholar
  21. 21.
    Mentis N, Vardarli I, Köthe LD et al (2011) GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60(4):1270–1276.  https://doi.org/10.2337/db10-1332 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Schmitt C, Portron A, Jadidi S et al (2017) Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab 19(10):1436–1445.  https://doi.org/10.1111/dom.13024
  23. 23.
    Frias JP, Bastyr EJ, Vignati L et al (2017) The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26(2):343–352.e2.  https://doi.org/10.1016/j.cmet.2017.07.011 CrossRefPubMedGoogle Scholar
  24. 24.
    Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180–2193.  https://doi.org/10.1016/S0140-6736(18)32260-8 CrossRefPubMedGoogle Scholar
  25. 25.
    DiMarchi RD (2018) “Let’s stay together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease. Mol Metab 18:1–2.  https://doi.org/10.1016/J.MOLMET.2018.10.004 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Finan B, Müller TD, Clemmensen C et al (2016) Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med 22(5):359–376.  https://doi.org/10.1016/j.molmed.2016.03.005 CrossRefPubMedGoogle Scholar
  27. 27.
    Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8(7):738–742.  https://doi.org/10.1038/nm727 CrossRefPubMedGoogle Scholar
  28. 28.
    McClean PL, Irwin N, Cassidy RS et al (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293(6):E1746–E1755.  https://doi.org/10.1152/ajpendo.00460.2007 CrossRefPubMedGoogle Scholar
  29. 29.
    Althage MC, Ford EL, Wang S et al (2008) Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 283(26):18365–18376.  https://doi.org/10.1074/jbc.M710466200 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kim SJ, Nian C, Karunakaran S et al (2012) GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7(7):e40156.  https://doi.org/10.1371/journal.pone.0040156 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sparre-Ulrich AH, Hansen LS, Svendsen B et al (2016) Species-specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol 173(1):27–38.  https://doi.org/10.1111/bph.13323 CrossRefPubMedGoogle Scholar
  32. 32.
    Vilsbøll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide – regardless of etiology and phenotype. J Clin Endocrinol Metab 88(10):4897–4903.  https://doi.org/10.1210/jc.2003-030738 CrossRefPubMedGoogle Scholar
  33. 33.
    Rudovich N, Pivovarova O, Gögebakan O et al (2015) Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance. Diabetes Care 38(1):e7–e8.  https://doi.org/10.2337/dc14-1452 CrossRefPubMedGoogle Scholar
  34. 34.
    Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects. Regul Pept 51(1):63–74.  https://doi.org/10.1016/0167-0115(94)90136-8 CrossRefPubMedGoogle Scholar
  35. 35.
    Nauck MA, Bartels E, Orskov C et al (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912–917PubMedGoogle Scholar
  36. 36.
    Knop FK, Aaboe K, Vilsbøll T et al (2012) Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14(6):500–510.  https://doi.org/10.1111/j.1463-1326.2011.01549.x CrossRefPubMedGoogle Scholar
  37. 37.
    Calanna S, Piro S, Di Pino A et al (2013) Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity 21(2):320–325.  https://doi.org/10.1002/oby.20017 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Natasha C. Bergmann
    • 1
    • 2
    • 3
  • Asger Lund
    • 1
    • 4
  • Lærke S. Gasbjerg
    • 1
    • 3
    • 5
  • Emma C. E. Meessen
    • 6
  • Maria M. Andersen
    • 1
  • Sigrid Bergmann
    • 1
  • Bolette Hartmann
    • 3
    • 5
  • Jens J. Holst
    • 3
    • 5
  • Lene Jessen
    • 2
  • Mikkel B. Christensen
    • 1
    • 7
    • 8
  • Tina Vilsbøll
    • 1
    • 8
  • Filip K. Knop
    • 1
    • 5
    • 8
    Email author
  1. 1.Clinical Metabolic PhysiologySteno Diabetes Center Copenhagen, Gentofte HospitalHellerupDenmark
  2. 2.Department of In Vivo PharmacologyZealand Pharma A/SGlostrupDenmark
  3. 3.Department of Biomedical Sciences, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of Medicine, Gentofte HospitalUniversity of CopenhagenHellerupDenmark
  5. 5.Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  6. 6.Department of Endocrinology and Metabolism, Amsterdam UMC, Academic Medical CenterUniversity of AmsterdamAmsterdamthe Netherlands
  7. 7.Department of Clinical PharmacologyBispebjerg Hospital, University of CopenhagenCopenhagenDenmark
  8. 8.Department of Clinical Medicine, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations